Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 4/2020

Open Access 01-12-2020 | Cardiomyopathy

Clinical manifestations and management of fatty acid oxidation disorders

Authors: J. Lawrence Merritt 2nd, Erin MacLeod, Agnieszka Jurecka, Bryan Hainline

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2020

Login to get access

Abstract

Fatty acid oxidation disorders (FAOD) are a group of rare, autosomal recessive, metabolic disorders caused by variants of the genes for the enzymes and proteins involved in the transport and metabolism of fatty acids in the mitochondria. Those affected by FAOD are unable to convert fatty acids into tricarboxylic acid cycle intermediates such as acetyl-coenzyme A, resulting in decreased adenosine triphosphate and glucose for use as energy in a variety of high-energy–requiring organ systems. Signs and symptoms may manifest in infants but often also appear in adolescents or adults during times of increased metabolic demand, such as fasting, physiologic stress, and prolonged exercise. Patients with FAOD present with a highly heterogeneous clinical spectrum. The most common clinical presentations include hypoketotic hypoglycemia, liver dysfunction, cardiomyopathy, rhabdomyolysis, and skeletal myopathy, as well as peripheral neuropathy and retinopathy in some subtypes. Despite efforts to detect FAOD through newborn screening and manage patients early, symptom onset can be sudden and serious, even resulting in death. Therefore, it is critical to identify quickly and accurately the key signs and symptoms of patients with FAOD to manage metabolic decompensations and prevent serious comorbidities.
Literature
1.
go back to reference Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304:H1060–76.PubMedPubMedCentral Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304:H1060–76.PubMedPubMedCentral
2.
go back to reference Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. W H Freeman: New York; 2002. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. W H Freeman: New York; 2002.
3.
go back to reference Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. West J Med. 1982;137:379–99.PubMedPubMedCentral Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. West J Med. 1982;137:379–99.PubMedPubMedCentral
4.
go back to reference Newsholme EA. The glucose/fatty acid cycle and physical exhaustion. CIBA Found Symp. 1981;82:89–101.PubMed Newsholme EA. The glucose/fatty acid cycle and physical exhaustion. CIBA Found Symp. 1981;82:89–101.PubMed
5.
go back to reference Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33:469–77.PubMedPubMedCentral Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33:469–77.PubMedPubMedCentral
6.
go back to reference Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477–502.PubMed Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477–502.PubMed
7.
go back to reference Schönfeld P, Wojtczak L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res. 2016;57:943–54.PubMedPubMedCentral Schönfeld P, Wojtczak L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res. 2016;57:943–54.PubMedPubMedCentral
8.
go back to reference El Bacha T, Luz MRMP, Da Poian AT. Dynamic adaptation of nutrient utilization in humans. Nat Educ. 2010;3:8. El Bacha T, Luz MRMP, Da Poian AT. Dynamic adaptation of nutrient utilization in humans. Nat Educ. 2010;3:8.
9.
go back to reference Knottnerus SJG, Bleeker JC, Wüst RCI, Ferdinandusse S, IJlst L, Wijburg FA, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19:93–106.PubMedPubMedCentral Knottnerus SJG, Bleeker JC, Wüst RCI, Ferdinandusse S, IJlst L, Wijburg FA, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19:93–106.PubMedPubMedCentral
10.
go back to reference Wanders RJ, Ruiter JP, IJlst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis. 2010;33:479–94.PubMedPubMedCentral Wanders RJ, Ruiter JP, IJlst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis. 2010;33:479–94.PubMedPubMedCentral
12.
go back to reference Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015;36:e00281.PubMed Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015;36:e00281.PubMed
13.
go back to reference Klose DA, Kölker S, Heinrich B, Prietsch V, Mayatepek E, von Kries R, et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics. 2002;110:1204–11.PubMed Klose DA, Kölker S, Heinrich B, Prietsch V, Mayatepek E, von Kries R, et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics. 2002;110:1204–11.PubMed
14.
go back to reference Janeiro P, Jotta R, Ramos R, Florindo C, Ventura FV, Vilarinho L, et al. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era. Eur J Pediatr. 2019;178:387–94.PubMed Janeiro P, Jotta R, Ramos R, Florindo C, Ventura FV, Vilarinho L, et al. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era. Eur J Pediatr. 2019;178:387–94.PubMed
15.
go back to reference Kang E, Kim Y-M, Kang M, Heo S-H, Kim G-H, Choi I-H, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr. 2018;18:103.PubMedPubMedCentral Kang E, Kim Y-M, Kang M, Heo S-H, Kim G-H, Choi I-H, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr. 2018;18:103.PubMedPubMedCentral
16.
go back to reference Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010;33:521–6.PubMed Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010;33:521–6.PubMed
18.
go back to reference Huang H-P, Chu K-L, Chien Y-H, Wie M-L, Wu S-T, Wang S-F, et al. Tandem mass neonatal screening in Taiwan—report from one center. Formos Med Assoc. 2006;105:882–6. Huang H-P, Chu K-L, Chien Y-H, Wie M-L, Wu S-T, Wang S-F, et al. Tandem mass neonatal screening in Taiwan—report from one center. Formos Med Assoc. 2006;105:882–6.
19.
go back to reference van Maldegem BT, Duran M, Wanders RJA, Niezen-Koning KE, Hogeveen M, Ijlst L, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme a dehydrogenase deficiency. JAMA. 2006;296:943–52.PubMed van Maldegem BT, Duran M, Wanders RJA, Niezen-Koning KE, Hogeveen M, Ijlst L, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme a dehydrogenase deficiency. JAMA. 2006;296:943–52.PubMed
20.
go back to reference Gallant NM, Leydiker K, Tang H, Feuchtbaum L, Lorey F, Puckett R, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol Genet Metab. 2012;106:55–61.PubMed Gallant NM, Leydiker K, Tang H, Feuchtbaum L, Lorey F, Puckett R, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol Genet Metab. 2012;106:55–61.PubMed
21.
go back to reference Oliveira SF, Pinho L, Rocha H, Nogueira C, Vilarinho L, Dinis MJ, et al. Rhabdomyolysis as a presenting manifestation of very long-chain acyl-coenzyme a dehydrogenase deficiency. Clin Pract. 2013;3:e22.PubMedPubMedCentral Oliveira SF, Pinho L, Rocha H, Nogueira C, Vilarinho L, Dinis MJ, et al. Rhabdomyolysis as a presenting manifestation of very long-chain acyl-coenzyme a dehydrogenase deficiency. Clin Pract. 2013;3:e22.PubMedPubMedCentral
22.
go back to reference Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, et al. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab. 2016;119:223–31.PubMedPubMedCentral Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, et al. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab. 2016;119:223–31.PubMedPubMedCentral
23.
go back to reference Saudubray JM, Martin D, de Lonlay P, Touati G, Poggi-Travert F, Bonnet D, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22:487–502. Saudubray JM, Martin D, de Lonlay P, Touati G, Poggi-Travert F, Bonnet D, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22:487–502.
24.
go back to reference Topçu Y, Bayram E, Karaoğlu P, Yiş U, Kurul SH. Importance of acylcarnitine profile analysis for disorders of lipid metabolism in adolescent patients with recurrent rhabdomyolysis: report of two cases. Ann Indian Acad Neurol. 2014;17:437–40.PubMedPubMedCentral Topçu Y, Bayram E, Karaoğlu P, Yiş U, Kurul SH. Importance of acylcarnitine profile analysis for disorders of lipid metabolism in adolescent patients with recurrent rhabdomyolysis: report of two cases. Ann Indian Acad Neurol. 2014;17:437–40.PubMedPubMedCentral
25.
go back to reference Vavlukis M, Eftimov A, Zafirovska P, Caparovska E, Pocesta B, Kedev S, et al. Rhabdomyolysis and cardiomyopathy in a 20-year-old patient with CPT II deficiency. Case Rep Genet. 2014;2014:496410.PubMedPubMedCentral Vavlukis M, Eftimov A, Zafirovska P, Caparovska E, Pocesta B, Kedev S, et al. Rhabdomyolysis and cardiomyopathy in a 20-year-old patient with CPT II deficiency. Case Rep Genet. 2014;2014:496410.PubMedPubMedCentral
26.
go back to reference Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110:259–69.PubMedPubMedCentral Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110:259–69.PubMedPubMedCentral
27.
go back to reference Siddiq S, Wilson BJ, Graham ID, Lamoureux M, Khangura SD, Tingley K, et al. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11:168.PubMedPubMedCentral Siddiq S, Wilson BJ, Graham ID, Lamoureux M, Khangura SD, Tingley K, et al. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11:168.PubMedPubMedCentral
28.
go back to reference Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England newborn screening program. Clin Chem. 2001;47:1945–55.PubMed Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England newborn screening program. Clin Chem. 2001;47:1945–55.PubMed
29.
go back to reference Merritt JL, Vedal S, Abdenur JE, Au SM, Barshop BA, Feuchtbaum L, et al. Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening. Mol Genet Metab. 2014;111:484–92.PubMed Merritt JL, Vedal S, Abdenur JE, Au SM, Barshop BA, Feuchtbaum L, et al. Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening. Mol Genet Metab. 2014;111:484–92.PubMed
30.
go back to reference Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36:795–803.PubMed Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36:795–803.PubMed
31.
go back to reference Bleeker JC, Kok IL, Ferdinandusse S, van der Pol WL, Cuppen I, Bosch AM, et al. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. J Inherit Metab Dis. 2019;42:414–23.PubMed Bleeker JC, Kok IL, Ferdinandusse S, van der Pol WL, Cuppen I, Bosch AM, et al. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. J Inherit Metab Dis. 2019;42:414–23.PubMed
32.
go back to reference Gillingham M, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2003;79:114–23.PubMedPubMedCentral Gillingham M, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K, et al. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2003;79:114–23.PubMedPubMedCentral
33.
go back to reference Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32:498–505.PubMed Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32:498–505.PubMed
34.
go back to reference Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO. Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab. 2007;90:64–9.PubMed Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO. Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab. 2007;90:64–9.PubMed
35.
go back to reference Blau N, Hoffmann GF, Leonard JV, Clarke JTR. Physician’s guide to the treatment and follow-up of metabolic diseases. New York: Springer; 2014. Blau N, Hoffmann GF, Leonard JV, Clarke JTR. Physician’s guide to the treatment and follow-up of metabolic diseases. New York: Springer; 2014.
36.
go back to reference Behrend AM, Harding CO, Shoemaker JD, Matern D, Sahn DJ, Elliot DL, et al. Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation. Mol Genet Metab. 2012;105:110–5.PubMed Behrend AM, Harding CO, Shoemaker JD, Matern D, Sahn DJ, Elliot DL, et al. Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation. Mol Genet Metab. 2012;105:110–5.PubMed
37.
go back to reference Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, et al. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment—a retrospective chart review. Mol Genet Metab. 2015;116:53–60.PubMedPubMedCentral Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, et al. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment—a retrospective chart review. Mol Genet Metab. 2015;116:53–60.PubMedPubMedCentral
40.
go back to reference Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol. 2007;24:15–25.PubMedPubMedCentral Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol. 2007;24:15–25.PubMedPubMedCentral
41.
go back to reference Gosalakkal JA, Kamoji V. Reye syndrome and Reye-like syndrome. Pediatr Neurol. 2008;39:198–200.PubMed Gosalakkal JA, Kamoji V. Reye syndrome and Reye-like syndrome. Pediatr Neurol. 2008;39:198–200.PubMed
42.
go back to reference Tein I. Disorders of fatty acid oxidation. Handb Clin Neurol. 2013;113:1675–88.PubMed Tein I. Disorders of fatty acid oxidation. Handb Clin Neurol. 2013;113:1675–88.PubMed
44.
go back to reference Marles SL, Casiro OG. Persistent neonatal hypoglycemia: diagnosis and management. Paediatr Child Health. 1998;3:16–9.PubMedPubMedCentral Marles SL, Casiro OG. Persistent neonatal hypoglycemia: diagnosis and management. Paediatr Child Health. 1998;3:16–9.PubMedPubMedCentral
45.
go back to reference El-Gharbawy A, Vockley J. Inborn errors of metabolism with myopathy: defects of fatty acid oxidation and the carnitine shuttle system. Pediatr Clin N Am. 2018;65:317–35. El-Gharbawy A, Vockley J. Inborn errors of metabolism with myopathy: defects of fatty acid oxidation and the carnitine shuttle system. Pediatr Clin N Am. 2018;65:317–35.
46.
go back to reference Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis. 2010;33:527–32.PubMed Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis. 2010;33:527–32.PubMed
47.
go back to reference Ibdah JA, Tein I, Dionisi-Vici C, Bennett MJ, IJist L, Gibson B, et al. Mild trifunctional protein deficiency is associated with progressive neuropathy and myopathy and suggests a novel genotype-phenotype correlation. J Clin Invest. 1998;102:1193–9.PubMedPubMedCentral Ibdah JA, Tein I, Dionisi-Vici C, Bennett MJ, IJist L, Gibson B, et al. Mild trifunctional protein deficiency is associated with progressive neuropathy and myopathy and suggests a novel genotype-phenotype correlation. J Clin Invest. 1998;102:1193–9.PubMedPubMedCentral
48.
go back to reference Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33:555–61.PubMed Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33:555–61.PubMed
49.
go back to reference Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013;17:260–8.PubMedPubMedCentral Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013;17:260–8.PubMedPubMedCentral
50.
go back to reference Strandqvist A, Haglind CB, Zetterström RH, Nemeth A, von Döbeln U, Stenlid MH, et al. Neuropsychological development in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. JIMD Rep. 2016;28:75–84.PubMed Strandqvist A, Haglind CB, Zetterström RH, Nemeth A, von Döbeln U, Stenlid MH, et al. Neuropsychological development in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. JIMD Rep. 2016;28:75–84.PubMed
51.
go back to reference Fletcher AL, Pennesi ME, Harding CO, Weleber RG, Gillingham MB. Observations regarding retinopathy in mitochondrial trifunctional protein deficiencies. Mol Genet Metab. 2012;106:18–24.PubMedPubMedCentral Fletcher AL, Pennesi ME, Harding CO, Weleber RG, Gillingham MB. Observations regarding retinopathy in mitochondrial trifunctional protein deficiencies. Mol Genet Metab. 2012;106:18–24.PubMedPubMedCentral
52.
go back to reference Goetzman ES. Advances in the understanding and treatment of mitochondrial fatty acid oxidation disorders. Curr Genet Med Rep. 2017;5:132–42.PubMedPubMedCentral Goetzman ES. Advances in the understanding and treatment of mitochondrial fatty acid oxidation disorders. Curr Genet Med Rep. 2017;5:132–42.PubMedPubMedCentral
53.
go back to reference Feillet F, Stinmann G, Vianey-Saban C, de Chillou C, Sadoul N, Lefebvre E, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med. 2003;29:1594–7.PubMed Feillet F, Stinmann G, Vianey-Saban C, de Chillou C, Sadoul N, Lefebvre E, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med. 2003;29:1594–7.PubMed
54.
go back to reference Mayell SJ, Edwards L, Reynolds FE, Chakrapani AB. Late presentation of medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2007;30:104.PubMed Mayell SJ, Edwards L, Reynolds FE, Chakrapani AB. Late presentation of medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2007;30:104.PubMed
55.
go back to reference McCoin CS, Gillingham MB, Knotts TA, Vockley J, Ono-Moore KD, Blackburn ML, et al. Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders. Physiol Rep. 2019;7:e14037.PubMedPubMedCentral McCoin CS, Gillingham MB, Knotts TA, Vockley J, Ono-Moore KD, Blackburn ML, et al. Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders. Physiol Rep. 2019;7:e14037.PubMedPubMedCentral
56.
go back to reference Bougnères PF, Karl IE, Hillman LS, Bier DM. Lipid transport in the human newborn. Palmitate and glycerol turnover and the contribution of glycerol to neonatal hepatic glucose output. J Clin Invest. 1982;70:262–70.PubMedPubMedCentral Bougnères PF, Karl IE, Hillman LS, Bier DM. Lipid transport in the human newborn. Palmitate and glycerol turnover and the contribution of glycerol to neonatal hepatic glucose output. J Clin Invest. 1982;70:262–70.PubMedPubMedCentral
57.
go back to reference Bonnett D, Martin D, de Lonlay P, Villain E, Jouvet P, Rabier D, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999;100:2248–53. Bonnett D, Martin D, de Lonlay P, Villain E, Jouvet P, Rabier D, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999;100:2248–53.
58.
59.
go back to reference Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, Vockley J, et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation. 1999;99:1337–43.PubMed Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, Vockley J, et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation. 1999;99:1337–43.PubMed
60.
go back to reference Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124:2761–2796. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124:2761–2796.
61.
go back to reference Lüderitz B, Jung W. Quality of life in patients with atrial fibrilation. Arch Intern Med. 2000;160:1749–57.PubMed Lüderitz B, Jung W. Quality of life in patients with atrial fibrilation. Arch Intern Med. 2000;160:1749–57.PubMed
62.
go back to reference Steptoe A, Mohabir A, Mahon NG, McKenna WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000;83:645–50.PubMedPubMedCentral Steptoe A, Mohabir A, Mahon NG, McKenna WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000;83:645–50.PubMedPubMedCentral
63.
go back to reference Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C:77–85.PubMedPubMedCentral Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C:77–85.PubMedPubMedCentral
64.
go back to reference Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998;102:E69.PubMed Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998;102:E69.PubMed
65.
go back to reference Walter JH. Tolerance to fast: rational and practical evaluation in children with hypoketonaemia. J Inherit Metab Dis. 2009;32:214–7.PubMed Walter JH. Tolerance to fast: rational and practical evaluation in children with hypoketonaemia. J Inherit Metab Dis. 2009;32:214–7.PubMed
66.
go back to reference Tyni T, Kivelä T, Lappi M, Summanen P, Nikoskelainen E, Pihko H. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy. Ophthalmology. 1998;105:810–24.PubMed Tyni T, Kivelä T, Lappi M, Summanen P, Nikoskelainen E, Pihko H. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy. Ophthalmology. 1998;105:810–24.PubMed
67.
go back to reference Alonso EM. Acute liver failure in children: the role of defects in fatty acid oxidation. Hepatology. 2005;41:696–9.PubMed Alonso EM. Acute liver failure in children: the role of defects in fatty acid oxidation. Hepatology. 2005;41:696–9.PubMed
68.
go back to reference Kalra S, Mukherjee JJ, Venkataraman S, Bantwal G, Shaikh S, Saboo B, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17:819–34.PubMedPubMedCentral Kalra S, Mukherjee JJ, Venkataraman S, Bantwal G, Shaikh S, Saboo B, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17:819–34.PubMedPubMedCentral
69.
go back to reference Karaivazoglou K, Kalogeropoulou M, Assimakopoulos S, Triantos C. Psychosocial issues in pediatric nonalcoholic fatty liver disease. Psychosomatics. 2019;60:10–7.PubMed Karaivazoglou K, Kalogeropoulou M, Assimakopoulos S, Triantos C. Psychosocial issues in pediatric nonalcoholic fatty liver disease. Psychosomatics. 2019;60:10–7.PubMed
70.
go back to reference Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015;5:S42–8.PubMed Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015;5:S42–8.PubMed
71.
go back to reference Diekman EF, Visser G, Schmitz JP, Nievelstein RA, de Sain-van der Velden M, Wardrop M, et al. Altered energetics of exercise explain risk of rhabdomyolysis in very long-chain acyl-CoA dehydrogenase deficiency. PLoS One. 2016;11:e0147818.PubMedPubMedCentral Diekman EF, Visser G, Schmitz JP, Nievelstein RA, de Sain-van der Velden M, Wardrop M, et al. Altered energetics of exercise explain risk of rhabdomyolysis in very long-chain acyl-CoA dehydrogenase deficiency. PLoS One. 2016;11:e0147818.PubMedPubMedCentral
72.
go back to reference Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol. 2000;11:1553–61.PubMed Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol. 2000;11:1553–61.PubMed
73.
go back to reference Zweers H, Timmer C, Rasmussen E, den Heijer M, de Valk H. Successful weight loss in two adult patients diagnosed with late-onset long-chain fatty acid oxidation defect. JIMD Rep. 2012;6:127–9.PubMedPubMedCentral Zweers H, Timmer C, Rasmussen E, den Heijer M, de Valk H. Successful weight loss in two adult patients diagnosed with late-onset long-chain fatty acid oxidation defect. JIMD Rep. 2012;6:127–9.PubMedPubMedCentral
74.
go back to reference Gillingham M, Elizondo G, Behrend AM, Matern D, Schoeller DA, Harding CO, et al. Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders. J Inherit Metab Dis. 2019;42:857–69.PubMedPubMedCentral Gillingham M, Elizondo G, Behrend AM, Matern D, Schoeller DA, Harding CO, et al. Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders. J Inherit Metab Dis. 2019;42:857–69.PubMedPubMedCentral
75.
go back to reference Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71:260–4.PubMedPubMedCentral Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71:260–4.PubMedPubMedCentral
77.
go back to reference Brown RL, Barrett AE. Visual impairment and quality of life among older adults: an examination of explanations for the relationship. J Gerontol B Psychol Sci Soc Sci. 2011;66:364–73.PubMed Brown RL, Barrett AE. Visual impairment and quality of life among older adults: an examination of explanations for the relationship. J Gerontol B Psychol Sci Soc Sci. 2011;66:364–73.PubMed
78.
go back to reference Preece MA, Green A. Pregnancy and inherited metabolic disorders: maternal and fetal complications. Ann Clin Biochem. 2002;39:444–55.PubMed Preece MA, Green A. Pregnancy and inherited metabolic disorders: maternal and fetal complications. Ann Clin Biochem. 2002;39:444–55.PubMed
79.
go back to reference Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R–86R.PubMedPubMedCentral Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R–86R.PubMedPubMedCentral
Metadata
Title
Clinical manifestations and management of fatty acid oxidation disorders
Authors
J. Lawrence Merritt 2nd
Erin MacLeod
Agnieszka Jurecka
Bryan Hainline
Publication date
01-12-2020
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2020
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09568-3

Other articles of this Issue 4/2020

Reviews in Endocrine and Metabolic Disorders 4/2020 Go to the issue